Biosplice Therapeutics

Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Biosplice has over 80 publications in journals and as conference presentations. The company is headquartered in San Diego, California.

The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Private Equity15 Apr, 2021
***
***
***
Series B6 Aug, 2018
***
***
***
Series B1 Jan, 2016
***
***
***
Series A1 Oct, 2013
***
***
***
Capitalization1 Jan, 2012
***
***
***
Accelerator1 Jan, 2008
***
***
***

*** - To view the data, please log into your account or create a new one.

News related to Biosplice Therapeutics25

Filter by
Sort by
Biosplice Therapeutics
Sep 12, 2024 Show on chart

Biosplice Therapeutics Announces Initiation of Acute Myeloid ...

Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute ...

https://finance.yahoo.com/news/biosplice-therapeutics-announces-initiation-acute-110000507.html
Biosplice Therapeutics
Mar 9, 2024 Show on chart

Biosplice Therapeutics Announces Department of Defense (DoD ...

Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program · About ...

https://markets.businessinsider.com/news/stocks/biosplice-therapeutics-announces-department-of-defense-dod-award-to-fund-collaboration-with-the-roskamp-institute-to-advance-its-neurology-program-1033147516
Biosplice Therapeutics
Mar 8, 2024 Show on chart

Biosplice Therapeutics Announces Department of Defense (DoD ...

Yahoo · Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program....

https://finance.yahoo.com/news/biosplice-therapeutics-announces-department-defense-183600525.html
Biosplice Therapeutics
Sep 21, 2021 Show on chart

Week in review: Everest announces 2 in-licensings with total value ...

Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Sinovent and SinoMab Bio for $561 mln. Cue Health filed for a $180 mln IPO ...

https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion
Show more (20)

Investors5

Sands Capital VenturesSands Capital Ventures
aMoon FundaMoon Fund
Esas VenturesEsas Ventures
Vickers Venture PartnersVickers Venture Partners
Eventide Asset ManagementEventide Asset Management